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Abstract
Connexin43 (Cx43) forms gap junction channels and hemichannels that allow the communication 
among osteocytes, osteoblasts, and osteoclasts. Cx43 carboxy-terminal (CT) domain regulates 
channel opening and intracellular signaling by acting as a scaffold for structural and signaling 
proteins. To determine the role of Cx43 CT domain in bone, mice in which one allele of full 
length Cx43 was replaced by a mutant lacking the CT domain (Cx43ΔCT/fl) were studied. 
Cx43ΔCT/fl mice exhibit lower cancellous bone volume but higher cortical thickness than Cx43fl/fl 
controls, indicating that the CT domain is involved in normal cancellous bone gain but opposes 
cortical bone acquisition. Further, Cx43ΔCT is able to exert the functions of full length osteocytic 
Cx43 on cortical bone geometry and mechanical properties, demonstrating that domains other than 
the CT are responsible for Cx43 function in cortical bone. In addition, parathyroid hormone (PTH) 
failed to increase endocortical bone formation or energy to failure, a mechanical property that 
indicates resistance to fracture, in cortical bone in Cx43ΔCT mice with or without osteocytic full 
length Cx43. On the other hand, bone mass and bone formation markers were increased by the 
hormone in all mouse models, regardless of whether full length or Cx43ΔCT were or not expressed. 
We conclude that Cx43 CT domain is involved in proper bone acquisition; and that Cx43 
expression in osteocytes is dispensable for some but not all PTH anabolic actions.
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Introduction
Connexins are ubiquitously expressed proteins that form channels on cell membranes. These 
molecules are structurally conserved and exhibit four transmembrane domains and the 
amino- and the carboxy-terminal (CT) domains facing the cytoplasm. The transmembrane 
domains form the pore of the channel and dictate the size and charge of the molecules that 
can pass through [1]; the N-terminal domain is part of the pore and controls voltage-induced 
gating [2]; and the CT domain modulates channel opening through changes in its 
phosphorylation status [3]. Further, the CT domain interacts with intracellular structural and 
catalytic proteins and through this scaffolding function it regulates subcellular localization 
of newly synthesized connexin proteins and their rate of degradation [3] as well as cell 
behavior through changes in gene expression and modulation of pro-survival signaling 
pathways [4, 5]. Even though connexins exhibit high homology, the CT domains vary 
significantly among different members of the family, both in amino acid sequence and in 
length, giving distinct properties to each connexin [6].
Connexin 43 (Cx43), one of the most studied members of the connexin family, is highly 
expressed in bone cells [7–9]. Its expression is required for full differentiation and function 
of cells of both osteoblastic and osteoclastic lineage and for the maintenance of osteocyte 
viability [10]. In osteoblasts, deletion of Cx43 results in reduced levels of the transcription 
factor Runx2 and downstream osteoblastic genes including osteocalcin, and impaired 
mineralization in vitro and in vivo [11–15]. Another function of Cx43 in osteoblastic cells is 
protection from apoptosis, as demonstrated by accelerated spontaneous death of osteocytic 
cells silenced for Cx43 and high prevalence of osteocyte apoptosis in cortical bone of mice 
lacking Cx43 in osteoblasts and osteocytes or only in osteocytes [16–18]. Moreover, 
osteoblastic or osteocytic cells silenced for Cx43 are not protected by bisphosphonates or 
parathyroid hormone (PTH) from apoptosis induced by glucocorticoids or etoposide [16, 
19]. In the case of bisphosphonates, this lack of protection from glucocorticoid-induced 
apoptosis also occurs in vivo, in mice lacking Cx43 in osteoblasts and osteocytes [16]. The 
requirement of Cx43 for these anti-apoptotic actions is conferred by the cytoplasmic CT 
domain of the protein, as demonstrated by the inability of bisphosphonates/PTH to prevent 
apoptosis in cells expressing a truncated Cx43 mutant lacking the CT domain [19, 20]. The 
fact that preservation of osteoblast viability contributes at least in part to the anabolic effect 
of PTH in cancellous bone [21] and that mice lacking Cx43 in 2.3kb-col1a1-expressing 
osteoblastic cells exhibit a deficient response to intermittent PTH administration [12] 
suggests that Cx43 might be a central player for PTH action. However, the role of Cx43 
expression in particular in osteocytes as well as the CT domain for the anabolic effect of 
PTH on the skeleton has not been investigated.
Deletion of Cx43 from osteoblastic cells at different stages of differentiation leads to a 
reduction in cancellous bone, which is progressively less pronounced as the gene is deleted 
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in more differentiated cells of the lineage, with no effect when the gene is deleted from 
osteocytes [10]. On the other hand, cortical bone is similarly affected by deleting Cx43 at 
any stage of osteoblast differentiation. The resulting shared phenotype is characterized by 
increased endocortical bone resorption and periosteal bone apposition leading to geometrical 
changes of the long bones, and reduced bone material strength. The fact that deletion of 
Cx43 from osteocytes recapitulates the phenotype and that expression of the gene in less 
mature cells is not sufficient to prevent it suggests that osteocytic Cx43 is the one required 
to achieve proper bone geometry and strength in cortical bone. However, the domain that 
mediates the functions of Cx43 is not known. Knock-in mice in which the full length Cx43 
is replaced by a truncated Cx43 mutant lacking the CT domain (named Cx43ΔCT) have been 
generated [22]. Expression of the truncated Cx43 has been demonstrated in these mice by 
Western blotting in epidermis, brain, and isolated astrocytes, indicating that the truncated 
protein is not unstable [22, 23]. Homozygous mice expressing two alleles of Cx43ΔCT die by 
dehydration soon after birth due to increased skin permeability. In contrast, mice expressing 
only one allele of the truncated gene have a less pronounced phenotype and reach adulthood 
[24, 25]. However, their skeletal phenotype has not been investigated.
We addressed in the current study three outstanding questions regarding the role of the 
scaffolding function of Cx43 mediated by its CT domain in bone: (1) whether the Cx43 CT 
domain dictates the functions of the entire Cx43 protein in cancellous and cortical bone; (2) 
whether the truncated Cx43ΔCT mutant lacking the CT domain is able to exert the functions 
of the full length Cx43 in osteocytes; and (3) whether expression of either full length Cx43 
or Cx43ΔCT in osteocytes is required for the effects of intermittent PTH administration in 
bone. We report that the Cx43 CT domain is involved in normal bone acquisition and bone 
formation in cancellous bone, but it is dispensable for cortical bone accrual. Moreover, 
truncated Cx43ΔCT is able to exert the functions of osteocytic full length Cx43 in cortical 
bone geometry, suggesting that the CT domain is not required. We also found that lack of 
full length osteocytic Cx43 or absence of the CT domain did not alter the actions of PTH on 
cancellous bone; however, the effects of PTH on cortical bone are impaired in the absence 
of Cx43 in osteocytes, and are not present even when the truncated Cx43 is expressed in 
osteocytes. These findings reveal that the scaffolding Cx43 CT domain mediates Cx43 
action in cancellous bone and the response to PTH on the endocortical bone surface.
Materials and Methods
Animals and treatment
Knock-in mice in which one allele of the endogenous Cx43 was replaced by a mutant 
Cx43K258stop allele, which consists of Cx43 molecule truncated at amino acid 258 in the 
CT domain (abbreviated as Cx43ΔCT) in all tissues, were generated by K. Willecke 
(Universität Bonn, Bonn, Germany) [22] and crossed with mice harboring the “floxed” 
Cx43 full length (abbreviated as Cx43fl/fl) [26] in order to obtain Cx43ΔCT/fl mice. These 
mice were then mated with Cx43fl/fl mice expressing Cre recombinase under control of a 
DNA fragment containing 8 kb of the murine dentin matrix protein 1 promoter (abbreviated 
as Cx43fl/fl;DMP1-8kb-Cre), which lacks Cx43 in osteocytes [18]. From this breeding, 4 
genotypes were generate, as follows: Cx43fl/fl, Cx43ΔCT/fl, Cx43fl/fl;DMP1-8kb-Cre, and 
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Cx43ΔCT/fl;DMP1-8kb-Cre. A schematic representation of the mice indicating the 
expression of full length and truncated Cx43 is shown in Fig. 1A. All animal lines were 
developed in a C57BL/6 background and littermates were used as controls. Mice were fed a 
regular diet and water ad libitum and maintained on a 12 h light/dark cycle. Four-month-old 
female mice were injected daily for 14 days with either vehicle (0.9% saline, 10 μM β-
mercaptoethanol and 0.01% acid acetic) or 100 ng/g of human PTH (1–34) (Bachem 
California Inc., Torrance, CA, USA) diluted in vehicle solution. For dynamic 
histomorphometric studies, mice received intraperitoneal injections of calcein (20 mg/kg, 
Sigma Chemical, St. Louis, MO, USA) and alizarin red (20 mg/kg, Sigma) 7 and 2 days 
before sacrifice, as published [27]. The protocols involving mice were approved by the 
Institutional Animal Care and Use Committee of Indiana University School of Medicine.
Bone mineral density and micro-computed tomography analysis
Bone mineral density (BMD) was measured monthly by dual x-ray absorptiometry (DXA) 
using a PIXImus densitometer (G.E. Medical Systems, Lunar Division, Madison, WI, USA). 
BMD measurements included total BMD (excluding the head and tail), entire femur 
(femoral BMD) and L1–L6 vertebra (spinal BMD) [27]. Calibration was performed before 
scanning with a standard phantom, as recommended by the manufacturer. For micro-
computed tomography (μCT) analysis, femora and L4 vertebrae from mice at 4.5 months of 
age were dissected, cleaned of soft tissue and frozen at −20°C until imaging, at 6 μm pixel 
resolution on a Skyscan 1172 (SkyScan, Kontich, Belgium) following standard procedures 
[28].
Serum markers of bone turnover
Blood was collected by cheek bleeding after approximately 6 hours of fasting. Plasma was 
collected, aliquoted, and stored at −80°C until used. Plasma osteocalcin (OCN) (Biomedical 
Technologies Inc., Soughton, MA, USA) and C-telopeptide fragments (CTX) (RatLaps, 
Immunodiagnostic Systems Inc., Fountain Hill, AZ, USA) were measured as published [18, 
27].
Bone histomorphometry
Vertebrae (L1–L3) were dissected and fixed in 10% neutral buffered formalin, and 
embedded in methyl methacrylate as published [27]. Static historphometric analysis was 
performed on von Kossa and TRAP stained-sections, for osteoblasts and osteoclast, 
respectively. Dynamic histomorphometric measurements were performed in unstained bone 
sections of femoral midshaft [27]. Histomorphometric analysis was performed using 
OsteoMeasure high resolution digital video system (OsteoMetrics Inc., Decatur, GA, USA). 
The terminology and units used are those recommended by the Histomorphometry 
Nomenclature Committee of the American Society for Bone and Mineral Research 
(ASBMR) [29].
Apoptosis
Osteocyte and osteoblast apoptosis was detected in vertebral bone sections by TdT-mediated 
dUTP nick-end labeling (TUNEL) using a modified version of a commercial kit (EMD 
Pacheco-Costa et al. Page 4
Bone. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Millipore, Billerica, MA) in sections counterstained with 2% methyl green, as previously 
described [18].
RNA extraction and quantitative PCR (qPCR)
RNA was purified from lumbar vertebrae using TRIzol (Invitrogen, Grand Island, NY). 
qPCR was performed as described [30], using the house-keeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), and the ΔCt method [30]. Primers and probes were 
commercially available (Applied Biosystems, Foster City, CA) or were designed using the 
Assay Design Center (Roche Applied Science, Indianapolis, IN).
Biomechanical testing
Three-point bending testing of the femoral midshaft was performed following previously 
published protocols [27]. Briefly, bones were thawed to room temperature, hydrated in 0.9% 
saline, and loaded to failure at 2 mm/min with force versus displacement data collected at 10 
Hz using a servo-hydraulic test system (TestResources Inc., Shakopee, MN, USA). Femora 
were loaded to failure in an anterior-posterior direction with the upper contact area at the 
mid-diaphysis (50% total bone length) and the bottom contact points centered around this 
point and separated by 8 mm. Structural mechanical properties, ultimate load, stiffness, and 
energy to failure were determined from the load-deformation curves using standard 
definitions while material-level estimations of ultimate stress, modulus, and toughness were 
calculated using standard equations. Cross-sectional moment of inertia and anterior-
posterior diameter were determined by μCT and were used to calculate material-level 
properties, as previously described [31].
Statistical analysis
Data were analyzed by using SigmaPlot (Systat Software Inc., San Jose, CA). Differences 
were considered significant for p<0.05. All values are reported as the mean ± standard 
deviation. Differences were evaluated by two-way ANOVA, with post-hoc analysis using 
Student-Newman-Keuls Method.
Results
Global absence of Cx43 CT domain decreases cancellous bone, independently of whether 
or not osteocytes express full length Cx43
As previously reported [18], deletion of Cx43 from osteocytes in Cx43fl/fl; DMP1-8kb-Cre 
did not alter body weight (Fig. 1B) or BMD at any site (Fig. 1C) between 1 and 4 months of 
age. Similarly, ubiquitous expression of the truncated Cx43 lacking the CT domain did not 
alter weight or BMD up to 4 months of age (Figs. 1B and C).
Analysis of bone microarchitecture of 4.5-month-old mice by μCT revealed that Cx43ΔCT/fl 
mice exhibit 30% lower cancellous (BV/TV) and trabecular number (Tb.N), and higher 
trabecular separation (Tb.Sp) in L4 vertebrae compared to Cx43fl/fl mice, without changes in 
trabecular thickness (Tb.Th) (Fig. 2A). A similar phenotype was found in the cancellous 
bone of the distal femora; with a more profound decrease in BV/TV and trabecular number 
in Cx43ΔCT/fl mice, compared to Cx43fl/fl littermates (Fig. 2B). Furthermore, BV/TV and 
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trabecular number were lower in mice expressing only the truncated mutant and lacking the 
full length Cx43 in osteocytes (Cx43ΔCT/fl;DMP1-8kb-Cre mice) compared to mice lacking 
Cx43 from osteocytes (Cx43fl/fl;DMP1-8kb-Cre mice) in both vertebra and distal femur, 
whereas trabecular separation was only increased in the distal femur (Fig. 2). This evidence 
suggests that expression of Cx43 and its CT domain of Cx43 in osteocytes is not required 
for achieving proper cancellous bone architecture, as mice lacking Cx43 from osteocytes, 
but not mice expressing the Cx43ΔCT exhibit normal cancellous bone volume. On the other 
hand, expression of Cx43ΔCT or deletion of full length Cx43 from osteocytes did not alter 
tissue material density in the cancellous bone of the vertebrae, or in cancellous and cortical 
bone of the femur (Table 1).
Absence of Cx43 CT domain leads to reduced osteoblast numbers
The decrease in bone volume in cancellous bone is accompanied by a decrease in osteoblast 
number and surface in Cx43ΔCT/fl (Fig. 3A). Deletion of the full allele of Cx43 from 
osteocytes in Cx43ΔCT/fl;DMP1-8kb-Cre mice did not further affect osteoblast number and 
surface. Consistent with the changes in osteoblast number, mineralizing surface was 
significantly decreased in Cx43ΔCT/fl and Cx43ΔCT/fl;DMP1-Cre mice, resulting in reduced 
bone formation rate, even though mineral apposition rate was not changed (Fig. 3B). 
Osteoclast surface and number were not affected by the truncated Cx43 (Fig. 3C).
Taken together, these pieces of evidence suggest that the decrease in bone volume is due to 
defective osteoblastic bone formation, rather than to an increase in osteoclastic bone 
resorption.
Expression of the truncated Cx43 did not alter the prevalence of apoptosis of cancellous 
osteoblasts and osteocytes, or of cortical osteocytes (Fig. 4). As found before, 
Cx43fl/fl;DMP1-8kb-Cre exhibit increased cortical osteocyte apoptosis without changes in 
the prevalence of apoptosis of cancellous osteocytes and osteoblasts [16, 18]. Cx43 lacking 
the C-terminus tail was able to compensate for the absence of osteocytic full-length Cx43 
maintaining cortical osteocyte viability, suggesting that Cx43 C-terminus domain is not 
required for the survival of cortical osteocytes.
Cortical bone geometry and strength are preserved in mice expressing Cx43 lacking the 
CT domain in the absence osteocytic Cx43
Structural and biomechanical studies of the cortical bone of the femur shows that global 
expression of the truncated Cx43 has no effect on its own, except for an increase in 
mechanical stiffness, and ultimate and yield load compared to Cx43fl/fl mice (Figs. 5 and 
6A). As found before [18], deletion of Cx43 from osteocytes results in reduced cortical bone 
area, and increased periosteal perimeter and marrow cavity area in the femoral midshaft 
(Fig. 5A). In addition, Cx43fl/fl;DMP1-8kb-Cre mice exhibit decreased material properties 
(Fig. 5C), and no change in mechanical properties (Fig. 6) at this site. Some of the changes 
in bone geometry and mechanical properties found in mice lacking Cx43 in osteocytes were 
absent in mice expressing the Cx43ΔCT mutant (Figs. 5 and 6). In particular, the decrease in 
cortical bone area/tissue area, ultimate stress and material stiffness (elastic modulus), and 
the increase in periosteal perimeter and marrow cavity area at the mid-diaphysis found in 
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Cx43fl/fl;DMP1-Cre mice were not present in mice expressing only the truncated mutant of 
Cx43 in osteocytes (Cx43ΔCT/fl;DMP1-Cre mice). This suggests that the function of Cx43 
CT is not required for proper cortical bone structure and mechanical function.
Expression of truncated Cx43 increased femoral mechanical properties in the presence and 
absence of full length Cx43 in the osteocytes (Fig. 6A). Stiffness was higher in Cx43ΔCT/fl 
and Cx43ΔCT/fl;DMP1-Cre mice compared to Cx43fl/fl and Cx43fl/fl;DMP1-Cre littermates, 
respectively. A similar tendency was observed for ultimate load and yield load, although in 
this case only the difference between Cx43ΔCT/fl and Cx43fl/fl mice, but not between 
Cx43ΔCT/fl;DMP1-Cre and Cx43fl/fl;DMP1-Cre mice reached significance (Fig. 6A). Energy 
to failure and post-yield energy to failure, measurements that indicate the resistance of bone 
to fracture, were not affected by expressing the truncated Cx43 molecule (Fig. 6B).
Intermittent PTH administration led to a small but significant increase in ultimate load in 
Cx43fl/fl mice (Fig. 6A). On the other hand, PTH increased energy to failure and post-yield 
energy to failure in Cx43fl/fl mice, but not in littermates expressing Cx43ΔCT and/or lacking 
full length Cx43 in osteocytes (Fig. 6B). This suggests that the presence of Cx43 CT domain 
in osteocytes is required for the improvements in mechanical properties induced by 
intermittent PTH administration.
Expression of full length Cx43 in osteocytes and the scaffolding CT domain of the protein 
are dispensable for the anabolic action of intermittent PTH administration
Intermittent PTH administration increased total body, spinal, and femoral BMD (Fig. 6C) 
and cancellous bone volume (Table 2) in the vertebra and femur.
Moreover, PTH increased osteoblast number and bone formation rate in lumbar vertebra 
independently of the mouse genotype when compared to the corresponding vehicle-treated 
littermates (Table 2). In addition, serum osteocalcin and the expression of the osteoblastic 
genes osteocalcin, collagen 1a1 and alkaline phosphatase were also increased in all mice that 
received PTH injection, independently of the genotype (Figs. 6D and E). On the other hand, 
neither the genotype nor the hormonal treatment altered the levels of the resorption marker 
CTX, even though there was a tendency towards lower CTX level in mice expressing the 
truncated Cx43, which did not reach significance (Fig. 6D).
Increased bone formation induced by intermittent PTH administration on endocortical 
surfaces is prevented by deleting Cx43 from osteocytes and by expressing the truncated 
Cx43 lacking the CT domain
Periosteal mineralizing surface, but not mineral apposition rate, was increased in vehicle-
treated mice expressing the truncated form of Cx43 lacking the CT domain in all tissues 
(Figs. 7A and B), similar to what is observed in Cx43fl/fl;DMP1-Cre mice lacking Cx43 in 
osteocytes (Figs. 7A and B and [18]). However, the difference in bone formation rate 
between Cx43ΔCT/fl mice and Cx43fl/fl littermate controls did not reach significance. 
Further, the presence of the truncated form of the molecule in mice with osteocytic deletion 
of the full length allele of Cx43 (Cx43ΔCT/fl;DMP1-Cre mice) was sufficient to maintain 
MS/BS and BFR, which were similar to control mice. On the other hand, deletion of Cx43 
CT did not alter bone formation on the endocortical bone surface (Figs. 7B and C).
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Intermittent PTH administration increased bone formation in both the periosteal and 
endocortical surfaces in Cx43fl/fl control mice, with about 300% higher BFR on the 
periosteum, due to increases in both MAR and MS/BS (Figs. 7A and B). The increased in 
BFR induced by PTH was only about 50% on the endosteum, and was only due to elevated 
MAR (Figs. 7C and B). Further, expression of the truncated form of Cx43 in Cx43ΔCT/fl and 
Cx43ΔCT/fl;DMP1-Cre mice abolished the effect of intermittent PTH administration on bone 
formation on the endocortical surface without affecting the response to the hormone on the 
periosteal surface (Fig. 7). Deletion of Cx43 from osteocytes prevented the increase in 
MS/BS on the periosteal surface induced by intermittent PTH, but BFR remained higher due 
to the increase in MAR (Fig. 7A). On the other hand, the increase in BFR induced by PTH 
on the endocortical surface was abolished in Cx43fl/fl;DMP1-Cre mice due to lower MAR 
(Fig. 7B). Taken together, these pieces of evidence suggest that expression of Cx43 in 
osteocytes, and in particular its CT domain, is required for the effect of PTH on bone 
formation on the endocortical bone surface.
Discussion
The findings of the present study demonstrate that Cx43 exerts a complex role on bone 
homeostasis through different domains of the protein. Absence of the cytoplasmic CT 
domain of Cx43 known to regulate channel closure and intracellular signaling induces a 
profound reduction in cancellous bone volume in the spine as well as in the long bones, as a 
consequence of low osteoblast number and bone formation. However, it does not affect 
cortical bone. These findings demonstrate that the CT domain of Cx43 exert distinct 
functions in osteoblastic cells in the two bone envelopes. Furthermore, the expression of the 
truncated form of Cx43 lacking the CT domain compensates for deletion of Cx43 from 
osteocytes and normalizes the increase in osteocyte apoptosis and the alterations on cortical 
bone geometry and mechanical properties, suggesting that in cortical bone osteocyte 
apoptosis, bone geometry, and material strength are closely correlated. Our findings suggest 
that Cx43 trasnmembrane, cytoplasmic, and/or amino domains, but not the CT domain, are 
required in osteocytes to control osteocyte survival and bone formation and resorption in 
cortical bone, resulting in proper bone geometry. However, we cannot rule out the 
possibility that Cx43ΔCT expressed in other cells compensates for the absence of the full 
length molecule in osteocytes. Moreover, mice expressing the truncated form of Cx43 
respond to PTH with increased bone formation on cancellous and periosteal bone surfaces, 
but not on endocortical bone surface, demonstrating that the CT domain is involved in part 
in the anabolic response to the hormone. This evidence indicates that the CT domain of 
Cx43 participates in cancellous bone acquisition and has a dominant negative effect over the 
full length molecule in this compartment, but it is dispensable for reaching proper cortical 
bone geometry. Furthermore, the CT domain of Cx43 participates in the response to 
intermittent PTH administration in cortical but not cancellous bone.
At this point it is not possible to determine whether the observed phenotype is due to the 
expression of one copy of the truncated Cx43 or the combination of the truncated form of 
Cx43 with the wild type allele. We can, however, discard the possibility that the phenotype 
is due to the presence of only one allele of full length Cx43 mice, since Cx43flox/− mice do 
not exhibit decreased cancellous bone volume, bone formation, or osteoblast number [12].
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The precise molecular mechanism underlying the differential phenotype in cancellous and 
cortical bone of mice lacking the Cx43 CT domain is not known. The CT domain of Cx43 
has scaffolding functions that regulate intracellular signaling [3] and osteoblasts in 
cancellous and cortical bone are likely influenced by different stimuli that trigger particular 
signaling pathways. Therefore, the different phenotype of these mice in cancellous versus 
cortical bone might result from regulation of different signaling pathways in the two 
envelopes.
Cx43 expression is required for the development and function of several cell types, 
including bone cells [10]. In addition to its well-recognized function in cell-to-cell 
communication through gap junction channels, Cx43 hemichannels are also active in 
unopposed plasma membranes, mediating the exchange of molecules between the cells and 
the extracellular milieu [1, 32]. Cx43 also acts as a scaffolding protein with the ability to 
foster interactions among molecules that participate in different intracellular signaling 
pathways, thereby regulating cell function [33]. This “channel independent” function is 
exerted by the CT domain of the connexin. Studies aiming to investigate the role of Cx43 
CT domain are challenged by the early lethality of mice expressing the truncated form of 
Cx43 [22]. Similarly to mice with complete absence of Cx43 [34], mice homozygous for 
Cx43ΔCT die soon after birth [22]. However, whereas Cx43−/− mice die due to cardiac 
malformation [34], Cx43ΔCT/ΔCT die due to defective epidermal barrier and dehydration 
[22], suggesting that the CT domain of the molecule is required for some, but not all 
functions of the gap junction protein. Consistent with the disparate role of the CT domain of 
Cx43 in different cell populations, we now demonstrate that the Cx43 CT domain is 
involved in achieving proper osteoblast number and bone formation in cancellous bone but 
not in osteoblast function in cortical bone, in osteoclast function, in the regulation of the 
expression of RANKL and OPG, or in the effects of osteocytic Cx43 on cortical bone 
geometry.
The disparate role of Cx43 domains in different compartment is further supported by a 
recent study with two mouse models expressing mutated forms of Cx43 in osteocytes; one 
with impaired cell-to-cell gap junction channel activity, but normal hemichannel function, 
and the other unable to form functional channels and hemichannels [35]. Mice with impaired 
gap junction activity in osteocytes but that still retained hemichannel function do not exhibit 
major differences in the skeleton, compared to wild type littermates. On the other hand, mice 
with impaired channel and hemichannel activity exhibit a cortical bone phenotype that 
resembles that of mice with deletion of Cx43 from osteocytes [18, 31] with increased 
marrow cavity area and periosteal apposition; but without changes in cancellous bone 
architecture. Taken together with the current study, this evidence support a differential effect 
of Cx43 domains in cancellous versus cortical bone.
Ex vivo studies pioneered by Civitelli and colleagues demonstrated that cells from bones of 
Cx43−/− mice showed delayed ossification, reduced expression of osteoblast markers, and 
deficient mineralization compared to wild type cells [11]. Tissue-specific deletion of Cx43 
provided a detailed account of the role of Cx43 in each bone cell type, demonstrating that 
Cx43 expression is required for normal osteoblastic gene expression and function [11, 12, 
18, 36–39], as well as for osteoclast differentiation and function [8, 40–42]. We found that 
Pacheco-Costa et al. Page 9
Bone. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the cancellous bone mass phenotype of our Cx43ΔCT/fl mice is closer to that of mice lacking 
Cx43 in osteoblast progenitors [12], suggesting that Cx43 CT domain is required early in 
osteoblast differentiation. However, since the Cx43ΔCT/fl do not exhibit low BMD or 
reduced femoral length unlike the mice lacking Cx43 in cells expressing dermo1-Cre [38], it 
is likely that the Cx43 CT domain is not required for proper function of 
osteochondroprogenitors.
Unlike Cx43 removal from early osteoblast progenitors, deletion of Cx43 from osteocytes 
does not affect cancellous bone but has a significant effect on cortical bone, with decreased 
bone volume, and increased total bone and marrow cavity area ([18] and this manuscript). 
Our previous study demonstrated that these effects of Cx43 deletion result from increased 
periosteal bone formation and endocortical bone resorption. Furthermore, deletion of 
osteocytic Cx43 results in altered bone material-level mechanical properties, with decreased 
stiffness, and increased osteocyte apoptosis. All these changes are absent when the truncated 
Cx43 lacking the CT is expressed, suggesting that the transmembrane pore and/or the 
cytoplasmic amino-terminal domains are sufficient to maintain osteocyte viability and to 
restrain bone formation and bone resorption, leading to the normalization of the bone 
geometry, and to prevent the decrease in bone material properties of the cortical bone. On 
the other hand, Cx43 pore is not sufficient to mediate the role of the connexin on cancellous 
bone acquisition, suggesting that the scaffolding function of the CT domain or the regulation 
of channel activity are needed for proper osteoblast function in this bone envelope.
Even though previous studies using reporter mice show that DMP-8kb promoter not only 
targets osteocytes but also some osteoblasts [43], we showed that Cre recombinase under the 
control of the 8kb fragment of the DMP1 promoter is expressed in osteocytes and not in 
osteoblasts in our DMP1-8kb-Cre mice. This was evidenced by demonstrating that Cre is 
expressed in cells also expressing the osteocyte marker sclerostin and not in cells expressing 
the osteoblast marker keratocan [18]. Further, when the DMP1-8kb-Cre mice were used to 
delete Cx43 (Cx43fl/fl;DMP1-8kb-Cre mice), immunostaining with an anti-Cx43 antibody 
showed that Cx43 is still present in osteoblasts on the bone surface but it is absent from 
osteocytes within bone [18]. Therefore, the DMP1-8kb-Cre appears to selectively delete 
Cx43 from osteocytes and not from osteoblasts.
In the current study, we found that expression of the truncated Cx43 leads to decrease 
osteoblast number in cancellous bone without affecting osteoclast number or the levels of 
the resorption marker CTX in the circulation. This suggests that the Cx43 CT domain is 
intrinsically required for osteoblast but not for osteoclast differentiation and function. 
Consistent with the role of Cx43 in osteoblast differentiation, osteoblasts derived from mice 
with global deletion of Cx43 exhibit reduced expression of genes present in mature 
osteoblasts [11]. Further, overexpression of full-length Cx43 but not a truncated form of 
Cx43 lacking the C-terminus domain stimulates the expression of osteoblastic genes in 
MC3T3 osteoblastic cells in vitro [44]. Our findings also suggest that the Cx43ΔCT allele 
might act as a dominant negative for the full length molecule, as the phenotype is revealed 
even in the presence of one copy of the full-length Cx43 allele. Similarly, astrocytes from 
mice expressing one copy of the truncated Cx43 and one of the full length (wild type) allele 
(Cx43ΔCT/+) mice exhibit defective channel activity confirming that one allele of the mutant 
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acts as dominant negative over the full length Cx43 [23]. However, because mice used in the 
current study express the mutated molecule ubiquitously [22], future studies using mice with 
cell-specific expression of the truncated Cx43 will be required to identify the cell in which 
Cx43 CT domain exert its function regulating cancellous and cortical bone acquisition.
In spite of the effect of expression of the truncated Cx43 on the basal bone phenotype, 
Cx43ΔCT/fl mice respond to intermittent PTH administration with a comparable increase in 
bone mass, bone formation, gene expression, and circulating osteocalcin as control 
littermates that express only full length Cx43. Similar normal response to pharmacological 
treatments is observed in several genetically modified mice with low bone mass. Examples 
of this are mice lacking LRP5 treated with interemittent PTH [45] or with anti-sclerostin 
antibodies [46], and mice overexpressing DKK1 treated with intermittent PTH [47]. Taken 
together these pieces of evidence indicate that different stimuli are involved in bone mass 
acquisition and the response to pharmacological treatments.
We found that, unlike deletion of Cx43 from osteoblastic cells [12], deletion of Cx43 from 
osteocytes did not impair the increase in bone mass and cancellous bone formation in 
response to intermittent PTH administration. This contrasts with the lack of anabolic effect 
of mice lacking the PTH receptor in osteocytes, which do not respond to intermittent 
administration of the hormone [48, 49]. Taken together, these pieces of evidence suggest 
that while expression of Cx43 in osteocytes is not required for the increase in bone mass 
induced by intermittent administration of PTH, other osteocytic molecules activated 
downstream of the PTH receptor are responsible for the increase in bone mass induced by 
the hormonal treatment.
An additional finding that supports a complex role of Cx43 on the anabolic effect of 
intermittent PTH is the fact that bone formation on the endocortical surface of the femur is 
not increased in mice lacking Cx43 in osteocytes. Furthermore, in contrast to the ability of 
Cx43ΔCT to retain the function of full-length osteocytic Cx43 in cortical bone, expression of 
the truncated molecule in osteocytes cannot compensate for the lack of full length Cx43 in 
Cx43ΔCT/fl;DMP1-Cre mice on PTH-induced endocortical bone formation. Similarly, the 
increase in the amount of energy that the bone absorbs until it fails in the presence of PTH is 
absent in mice lacking Cx43 in osteocytes, or expressing only the truncated connexin in 
these cells. The reason for an abnormal response to PTH but normal cortical bone in mice 
lacking Cx43 CT domain might be due to the fact that different mechanisms control cortical 
bone formation in response to the hormone versus under normal conditions. Nevertheless, 
our evidence suggests that part of the PTH effect on cortical bone requires the presence of 
Cx43 CT domain in osteocytes.
The reason why bone cells from cortical versus cancellous bone of Cx43ΔCT mice respond 
differently to PTH is unknown. However, it could be due to the influence of different 
stimuli, to the fact that endogenous Cx43 is expressed at different levels in the two 
envelopes (lower in cancellous than cortical bone [18, 38]), or to both reasons. In any event, 
bone cells from these compartments are also differentially affected by expression of 
Cx43ΔCT. Moreover, several studies by the groups of Roberto Civitelli, Henry Donahue, 
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Jean Jiang, and us consistently demonstrated that manipulation of Cx43 in osteoblastic cells 
affects cortical and cancellous bone in a different manner [18, 35, 38, 39, 50, 51].
In summary, mice lacking Cx43 CT exhibit normal cortical bone but a marked decrease in 
cancellous bone accrual due to decreased osteoblast number and bone formation. In 
addition, Cx43 lacking the CT domain can compensate for the absence of full length Cx43 
in osteocytes. Further, mice lacking full length Cx43 in osteocytes or expressing the mutated 
Cx43 lacking the CT domain do not exhibit increased endocortical bone formation and bone 
strength induced by intermittent PTH administration, whereas they show a normal anabolic 
response to the hormone in cancellous bone or on the periosteal surface of cortical bone.
Conclusion
Our study establishes the requirement of distinct domains of Cx43 in different bone 
envelopes (cortical versus cancellous) and surfaces (endocortical versus periosteal) and in 
the regulation of hormonal responses by Cx43.
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Highlights
• Cx43 channels allow communication among bone cells, however, the role of its 
C-terminal domain (CT) on the skeleton is unknown.
• Removal of Cx43 CT results in decreased cancellous bone mass due to reduced 
osteoblast number and activity.
• Removal of Cx43 CT has no effect on cortical bone geometry or mechanical 
properties.
• The effects of PTH were less in mice lacking the Cx43 C-terminal domain 
compared to wild-type animals.
• Cx43 CT is involved in bone acquisition; and osteocytic Cx43 is dispensable for 
some but not all PTH anabolic actions
Pacheco-Costa et al. Page 16
Bone. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 1. Body weight and BMD are not affected by global absence of the Cx43 CT domain
(A) Cx43ΔCT/fl were mated with Cx43fl/fl;DMP1-8kb-Cre mice and 4 different genotypes 
were obtained: 1) Cx43fl/fl mice have both alleles of Cx43 gene flanked by LoxP sites and 
are similar to wild-type mice, 2) Cx43ΔCT/fl mice have one allele of Cx43 replaced by a 
Cx43 truncated at amino acid 258, which can generate functional channel but lacks the 
scaffolding ability, and the other allele is the full length floxed Cx43, 3) 
Cx43fl/fl;DMP1-8kb-Cre mice have both alleles flanked by LoxP sites and are recognized 
and excised by the Cre recombinase under control of a DNA fragment containing 8kb of the 
murine dentin matrix protein 1 promoter (DMP1), thus lacking Cx43 protein in osteocytes, 
and 4) Cx43ΔCT/fl;DMP1-Cre mice, expressing ubiquitously Cx43ΔCT and lacking 
osteocytic full length Cx43. (B) Body weight from mice of all genotypes was measured 
monthly from 1 to 4 months of age. Symbols represent mean ± s.d., n=12–28. (C) Total 
body, spinal, and femoral BMD was measured monthly from 1 to 4 months of age by dual-
DXA. Symbols represent mean ± s.d., n=12–28.
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Fig. 2. Absence of CT domain of Cx43 results in low cancellous bone volume
Cancellous bone microarchitecture was assessed in Cx43fl/fl, Cx43ΔCT/fl, 
Cx43fl/fl;DMP1-8kb-Cre, and Cx43ΔCT/fl;DMP1-8kb-Cre mice at 4.5 months of age by μCT 
in (A) L4 vertebrae and (B) distal femora. Representative reconstructed 3D μCT images are 
shown. Bars represent mean ± s.d., n=7–12. *p<0.05 versus Cx43fl/fl mice, and #p<0.05 
versus Cx43fl/fl;DMP1-8kb-Cre mice by two-way ANOVA.
Pacheco-Costa et al. Page 18
Bone. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 3. Deletion of Cx43 CT domain leads to decreased osteoblasts and bone formation, without 
affecting osteoclasts
Cell surface and number were measured in bone sections from lumbar vertebra obtained 
from 4.5 month-old-mice. (A) Osteoblasts were identified in bone sections stained by von 
Kossa/McNeal. Surface covered by osteoblasts (ObS/BS), number of osteoblasts per tissue 
area (NOb/TAr), and per bone surface (NOb/BPm) are reported. Representative images of 
von Kossa/McNeal stained bone sections are shown. Red arrows point at rows of 
osteoblasts. (B) Mineral apposition rate (MAR), mineralizing surface (MS/BS) and bone 
formation rate (BFR) were measured in unstained vertebral bone sections. Representative 
fluorescent images are shown. (C) Osteoclasts were identified in vertebral bone sections 
stained for TRAPase/Toluidine blue. Surface covered by osteoclasts (OcS/BS), osteoclast 
number per tissue area (NOc/TAr), and per bone surface (NOc/BPm) are reported. 
Representative images of bone sections stained for TRAP (red) are shown. Bars represent 
mean ± s.d., n=4. *p<0.05 versus Cx43fl/fl mice, and #p<0.05 versus Cx43fl/fl;DMP1-8kb-
Cre mice by two-way ANOVA.
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Fig. 4. Deletion of Cx43 CT reverses the increased cortical osteocyte apoptosis in mice lacking 
osteocytic Cx43
Apoptotic (TUNEL positive) cancellous osteoblasts and cancellous and cortical osteocytes 
were scored in vertebral bone. Bars represent mean ± s.d., n=4–9. #p<0.05 versus 
Cx43fl/fl;DMP1-8kb-Cre mice by two-way ANOVA.
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Fig. 5. Expression of truncated Cx43 is sufficient to maintain Cx43 function in cortical bone in 
mice lacking full length osteocytic Cx43
(A) Bone microarchitecture was evaluated in the femoral midshaft by μCT. n=9–10. * 
p<0.05 versus Cx43fl/fl mice, and #p<0.05 versus Cx43fl/fl:DMP1-8kb-Cre mice by two-way 
ANOVA. (B) Representative 3D μCT images of the femoral mid-diaphysis are shown. (C) 
Biomechanical properties were measured in femoral bone by 3-point bending testing. Bars 
represent mean ± s.d. n=7–10. *p<0.05 versus Cx43fl/fl mice, and #p<0.05 versus 
Cx43fl/fl;DMP1-8kb-Cre mice by two-way ANOVA.
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Fig. 6. Absence of Cx43 CT domain prevents the increase in resistance to fractures induced by 
intermittent PTH administration
(A and B) 3-point bending analysis of cortical bone of the femoral mid-diaphysis. (A) Bone 
material properties were assessed at the femoral midshaft. n=5–13. (B) Energy to failure and 
post-energy to failure were measured in the femoral midshaft. n=5–11. (C) Total body, 
spinal, and femoral BMD were measured after intermittent PTH administration by DXA in 
Cx43fl/fl, Cx43ΔCT/fl, Cx43fl/fl;DMP1-8kb-Cre, and Cx43ΔCT/fl;DMP1-8kb-Cre mice. n=7–
14 (D) Circulating levels for osteocalcin and CTX were measured by ELISA. n=7–14 (E) 
Expression of the indicated genes was measured by qPCR in whole lumbar vertebrae. Bars 
represent mean ± s.d. n=4–14. *p<0.05 versus Cx43fl/fl mice and Cx43fl/fl;DMP1-8kb-Cre 
for Cx43ΔCT/fl and Cx43ΔCT/fl;DMP1-8kb-Cre mice, respectively; and #p<0.05 versus 
corresponding vehicle-treated mice; by two-way ANOVA.
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Fig. 7. Cx43 CT is involved in intermittent PTH-induced bone formation on endocortical but not 
periosteal surface
(A) Periosteal mineral apposition rate (PsMAR), mineralizating surface (PsMS/BS), and 
bone formation rate (PsBFR/BS) were measured in unstained sections from femoral 
midshaft at 4.5 months of age. (B) Representative images show green and red fluorochrome 
labels. (C) Endosteal mineral apposition rate (EcMAR), mineralizating surface (EcMS/BS), 
and bone formation rate (EcBFR/BS) were measured in the same bone section as (A). Bars 
represent mean ± s.d., n=7/group. *p<0.05 versus Cx43fl/fl mice, and #p<0.05 versus 
corresponding vehicle-treated mice, by two-way ANOVA.
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Table 1
Global deletion of Cx43 CT domain or removal of the full length Cx43 from osteocytes does not affect bone 
material density in cancellous and cortical bone.
Material density (pixels) Cx43fl/fl Cx43ΔCT/fl Cx43fl/fl; DMP1-8kb-Cre Cx43ΔCT/fl; DMP1- 8kb-Cre
cancellous bone lumbar vertebra 129.04 ± 9.50 135.50 ± 3.05 130.92 ± 1.65 134.08 ± 2.17
cancellous bone distal femur 128.93 ± 3.78 127.81 ± 4.34 127.81 ± 5.10 128.37 ± 6.00
cortical bone femoral mid- diaphysis 185.11 ± 2.59 184.85 ± 2.93 181.56 ± 4.04 180.25 ± 7.44
n=7–12. No significant differences were found among groups.
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